CJC-1295 Research Overview

This overview sets out the research themes around CJC-1295, the stabilised GHRH analogue introduced in what is CJC-1295? It concerns the no-DAC material on the CJC-1295 product page, and keeps to areas of investigation rather than conclusions.

The central subject is the GHRH receptor. Investigators study how the analogue binds and activates that receptor on pituitary cells and how the downstream signalling compares with the response to natural GHRH. Because the receptor sits at the start of the growth-hormone secretagogue pathway, CJC-1295 serves as a tool for probing where in that pathway a stabilised agonist acts and how strongly.

Part of the work characterises the stabilising substitutions directly. Unmodified GHRH(1-29) is cut quickly by peptidases, and the substitutions in CJC-1295 are positioned to slow that cleavage, so studies measure how the analogue’s persistence in model systems compares with the native fragment. Showing that the substitutions extend persistence while keeping receptor activity intact is a question that joins stability measurement to receptor assays, and it is the kind of structure-to-function comparison that recurs across engineered research peptides.

A research theme specific to CJC-1295 is the effect of its substitutions. GHRH(1-29) is short-lived, so the analogue was designed to resist the enzymes that cut it. Studies therefore ask how much the substitutions extend persistence in model systems and whether they change receptor activity along the way. This makes the molecule a worked example of how a sequence can be engineered for stability while keeping its target, a question that connects to peptide degradation pathways.

Secretagogue research often examines a GHRH analogue together with a growth-hormone-releasing peptide, since the two act through different receptors. CJC-1295 features in that context alongside compounds such as the one covered in the ipamorelin research overview. Preclinical study describes these interactions in cell and model systems, where the reliability of any reading rests on well-characterised material, assessed by methods like those in HPLC analysis.

The rationale for pairing is receptor-level: a GHRH analogue and a ghrelin-receptor peptide act at different receptors on the same somatotroph cells, so studying them together lets researchers ask how the two inputs combine. CJC-1295 supplies the GHRH-receptor side of that question. Such designs call for careful controls, since the aim is to separate each input’s contribution rather than read a single merged response, and confirmed identity for each material remains a precondition for interpreting what the combination shows.

The evidence carries the usual caveats: model systems stand in for, without reproducing, full physiology; results depend on material quality and assay design; and the no-DAC and DAC forms must not be conflated when comparing studies. Open questions follow, from how precisely the substitutions tune persistence to how the analogue behaves in combination with other secretagogues. Keeping material steady for such work is covered in the CJC-1295 storage & handling guide.

All products are supplied strictly for laboratory research use only. Not for human or animal consumption. Not a drug, supplement, or food. Not for diagnostic or therapeutic use. The material on this page is educational and factual: it summarises areas of published scientific investigation and general laboratory practice. It is not guidance for the use of any material in humans or animals, and nothing here should be read as a claim about safety, performance, or outcomes. Where a specific product specification or safety data sheet is provided with a material, that document is the definitive reference and takes precedence over any general information given here.